BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform

Rhea-AI Summary

BioNxt Solutions (OTCQB:BNXTF) has reported significant progress on its targeted chemotherapy delivery platform, first announced in July 2025. The company's novel technology aims to concentrate chemotherapy drugs around tumors while protecting healthy tissue through a dual-action mechanism.

The platform has demonstrated potential for a 10-fold increase in therapeutic effect in vitro while maintaining healthy cell safety. The R&D team has created a molecule databank and identified numerous high-priority targets, with one promising candidate selected for proof of concept based on its pharmacokinetic properties.

The company expects to announce its patent strategy and next R&D steps soon, along with signing a definitive agreement in the coming weeks.

Positive

• Novel drug delivery platform shows 10-fold increase in therapeutic effect in vitro
• Dual-action mechanism potentially reduces systemic toxicity while maintaining efficacy
• Company has identified promising drug candidate for proof of concept
• Pending definitive agreement and patent strategy announcements

Negative

• Technology still in early development stage with only in-vitro data
• No clinical validation yet of the platform's effectiveness
• Timeline for definitive agreement completion remains uncertain

VANCOUVER, BC, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, is pleased to report a significant advancement regarding its targeted chemotherapy delivery platform and a related definitive transaction update.

First announced July 8, 2025, the novel technology is a potential breakthrough targeted chemotherapy delivery platform designed to address a critical unmet need by localizing toxic chemotherapy drugs inside and around tumours while minimizing systemic exposure. The proprietary targeted drug delivery system employs a novel, dual-action mechanism that first concentrates potent chemotherapy drugs in close proximity to tumours, then rapidly neutralizes free drug molecules outside of the tumour location to protect healthy tissue. This targeted approach has demonstrated in-vitro potential to enable a 10-fold increase in therapeutic effect while maintaining the safety of healthy cells, significantly expanding the therapeutic window.

The research and development team has initiated the creation of a molecule databank to feed prospective candidate molecules into the proprietary computational model to prioritize chemotherapy drugs for advanced research. The team has already identified a short-list of dozens of high-priority targets. From this short-list, the team is now focused on one drug shows particular promise for proof of concept due to its pharmacokinetic properties. The prioritized candidate is currently used in both traditional chemotherapy and in other advanced targeted oncology treatments.

The Company looks forward to announcing the next research and development steps and its patent strategy in the coming weeks and months. In addition, the Company expects to sign a definitive agreement in the coming weeks and will report an update accordingly.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.

With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3.

To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698

Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt

Cautionary Statement Regarding "Forward-Looking" Information

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

What is BioNxt's (BNXTF) new chemotherapy delivery platform?

BioNxt's platform is a dual-action mechanism that concentrates chemotherapy drugs around tumors while neutralizing free drug molecules outside the tumor area, potentially increasing therapeutic effect by 10-fold while protecting healthy tissue.

How does BioNxt's (BNXTF) targeted chemotherapy technology work?

The technology uses a proprietary dual-action mechanism that first concentrates chemotherapy drugs near tumors, then neutralizes free drug molecules outside the tumor location to protect healthy tissue.

What are the potential benefits of BioNxt's (BNXTF) chemotherapy platform?

The platform has shown potential for a 10-fold increase in therapeutic effect while maintaining healthy cell safety, potentially improving chemotherapy efficacy while reducing side effects.

What is the current development stage of BioNxt's (BNXTF) chemotherapy platform?

The platform is in early development with successful in-vitro testing. The company has created a molecule databank, identified high-priority targets, and selected a promising candidate for proof of concept.

When will BioNxt (BNXTF) announce its next development steps?

BioNxt plans to announce its patent strategy and next R&D steps in the coming weeks and months, along with signing a definitive agreement.